# A Phase Ib/IIa Study of INT-210 Capsules in Participants With Active Ulcerative Colitis

> **NCT07692165** · PHASE1,PHASE2 · RECRUITING · sponsor: **Innatus Therapeutics (Shanghai) Co., Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Ulcerative Colitis (UC)

## Interventions

- **DRUG:** INT-210 Capsule
- **DRUG:** INT-210 Capsule

## Key facts

- **NCT ID:** NCT07692165
- **Lead sponsor:** Innatus Therapeutics (Shanghai) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-11
- **Primary completion:** 2028-06
- **Final completion:** 2028-06
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07692165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07692165, "A Phase Ib/IIa Study of INT-210 Capsules in Participants With Active Ulcerative Colitis". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07692165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*